Published in Neuropharmacology on March 02, 2016
N-Methyl D-Aspartate Receptor Antagonist Kynurenic Acid Affects Human Cortical Development. Front Neurosci (2016) 0.75
Prenatal kynurenine exposure in rats: age-dependent changes in NMDA receptor expression and conditioned fear responding. Psychopharmacology (Berl) (2016) 0.75
Cross Talk: The Microbiota and Neurodevelopmental Disorders. Front Neurosci (2017) 0.75
Kynurenine aminotransferase 3/glutamine transaminase L/cysteine conjugate beta-lyase 2 is a major glutamine transaminase in the mouse kidney. Biochem Biophys Rep (2016) 0.75
Blockade of NMDA receptors and apoptotic neurodegeneration in the developing brain. Science (1999) 6.37
An endogenous tumour-promoting ligand of the human aryl hydrocarbon receptor. Nature (2011) 4.63
A neuronal nicotinic acetylcholine receptor subunit (alpha 7) is developmentally regulated and forms a homo-oligomeric channel blocked by alpha-BTX. Neuron (1990) 3.34
Kynurenines in the mammalian brain: when physiology meets pathology. Nat Rev Neurosci (2012) 3.11
Turning of nerve growth cones induced by neurotransmitters. Nature (1994) 3.06
The dynamic effects of nicotine on the developing brain. Pharmacol Ther (2009) 3.01
An iontophoretic investigation of the actions of convulsant kynurenines and their interaction with the endogenous excitant quinolinic acid. Brain Res (1982) 2.99
A transient placental source of serotonin for the fetal forebrain. Nature (2011) 2.71
Endogenous kynurenines as targets for drug discovery and development. Nat Rev Drug Discov (2002) 2.61
The brain metabolite kynurenic acid inhibits alpha7 nicotinic receptor activity and increases non-alpha7 nicotinic receptor expression: physiopathological implications. J Neurosci (2001) 2.61
Cortex-restricted disruption of NMDAR1 impairs neuronal patterns in the barrel cortex. Nature (2000) 2.60
Neuropharmacology of quinolinic and kynurenic acids. Pharmacol Rev (1993) 2.45
GABAA, NMDA and AMPA receptors: a developmentally regulated 'ménage à trois'. Trends Neurosci (1997) 2.35
Increased cortical kynurenate content in schizophrenia. Biol Psychiatry (2001) 2.27
Kynurenic acid as a ligand for orphan G protein-coupled receptor GPR35. J Biol Chem (2006) 2.16
Blood-brain barrier transport of kynurenines: implications for brain synthesis and metabolism. J Neurochem (1991) 2.01
Kynurenic acid is a potent endogenous aryl hydrocarbon receptor ligand that synergistically induces interleukin-6 in the presence of inflammatory signaling. Toxicol Sci (2010) 1.91
The aryl hydrocarbon receptor cross-talks with multiple signal transduction pathways. Biochem Pharmacol (2008) 1.90
Kynurenic acid levels are elevated in the cerebrospinal fluid of patients with schizophrenia. Neurosci Lett (2001) 1.89
Choline and selective antagonists identify two subtypes of nicotinic acetylcholine receptors that modulate GABA release from CA1 interneurons in rat hippocampal slices. J Neurosci (1999) 1.80
Endogenous kynurenate controls the vulnerability of striatal neurons to quinolinate: Implications for Huntington's disease. Exp Neurol (2005) 1.79
Kynurenine pathway metabolism in human astrocytes: a paradox for neuronal protection. J Neurochem (2001) 1.79
Epidemiology-driven neurodevelopmental animal models of schizophrenia. Prog Neurobiol (2009) 1.73
An evaluation of neuronal nicotinic acetylcholine receptor activation by quaternary nitrogen compounds indicates that choline is selective for the alpha 7 subtype. Neurosci Lett (1996) 1.67
Separable features of visual cortical plasticity revealed by N-methyl-D-aspartate receptor 2A signaling. Proc Natl Acad Sci U S A (2003) 1.66
Schizophrenia and the alpha7 nicotinic acetylcholine receptor. Int Rev Neurobiol (2007) 1.65
Impaired attention is central to the cognitive deficits observed in alpha 7 deficient mice. Eur Neuropsychopharmacol (2006) 1.62
Regulation of spine morphology and spine density by NMDA receptor signaling in vivo. Proc Natl Acad Sci U S A (2007) 1.58
Reduction of endogenous kynurenic acid formation enhances extracellular glutamate, hippocampal plasticity, and cognitive behavior. Neuropsychopharmacology (2010) 1.51
Expression of the kynurenine pathway enzyme tryptophan 2,3-dioxygenase is increased in the frontal cortex of individuals with schizophrenia. Neurobiol Dis (2004) 1.50
Elevated NMDA receptor levels and enhanced postsynaptic long-term potentiation induced by prenatal exposure to valproic acid. Proc Natl Acad Sci U S A (2007) 1.45
Increased levels of kynurenine and kynurenic acid in the CSF of patients with schizophrenia. Schizophr Bull (2010) 1.45
Upregulation of the initiating step of the kynurenine pathway in postmortem anterior cingulate cortex from individuals with schizophrenia and bipolar disorder. Brain Res (2006) 1.39
Apoptosis in the in vivo mammalian forebrain. Neurobiol Dis (2001) 1.36
Selective role of N-type calcium channels in neuronal migration. Science (1992) 1.34
Human microglia convert l-tryptophan into the neurotoxin quinolinic acid. Biochem J (1996) 1.32
Maternal infection and schizophrenia: implications for prevention. Schizophr Bull (2010) 1.32
Elevated levels of kynurenic acid in the cerebrospinal fluid of male patients with schizophrenia. Schizophr Res (2005) 1.32
Synthesis and biochemical evaluation of N-(4-phenylthiazol-2-yl)benzenesulfonamides as high-affinity inhibitors of kynurenine 3-hydroxylase. J Med Chem (1997) 1.31
Nanomolar concentrations of kynurenic acid reduce extracellular dopamine levels in the striatum. J Neurochem (2005) 1.31
The concept of progressive brain change in schizophrenia: implications for understanding schizophrenia. Schizophr Bull (2008) 1.30
Presynaptic alpha 7- and beta 2-containing nicotinic acetylcholine receptors modulate excitatory amino acid release from rat prefrontal cortex nerve terminals via distinct cellular mechanisms. Mol Pharmacol (2008) 1.29
The astrocyte-derived alpha7 nicotinic receptor antagonist kynurenic acid controls extracellular glutamate levels in the prefrontal cortex. J Mol Neurosci (2009) 1.28
Presynaptic kynurenate-sensitive receptors inhibit glutamate release. Eur J Neurosci (2001) 1.27
N-methyl-D-aspartate receptor antagonists disrupt the formation of a mammalian neural map. Proc Natl Acad Sci U S A (1992) 1.26
Nicotinic receptors in the rat prefrontal cortex: increase in glutamate release and facilitation of mediodorsal thalamo-cortical transmission. Eur J Neurosci (1999) 1.25
Expression of indoleamine 2,3-dioxygenase and tryptophan 2,3-dioxygenase in early concepti. Biochem J (2001) 1.25
Long-term behavioural, molecular and morphological effects of neonatal NMDA receptor antagonism. Eur J Neurosci (2003) 1.23
Targeted deletion of the kynurenine aminotransferase ii gene reveals a critical role of endogenous kynurenic acid in the regulation of synaptic transmission via alpha7 nicotinic receptors in the hippocampus. J Neurosci (2004) 1.23
Downregulated kynurenine 3-monooxygenase gene expression and enzyme activity in schizophrenia and genetic association with schizophrenia endophenotypes. Arch Gen Psychiatry (2011) 1.22
Hypoxia and brain development. Prog Neurobiol (1996) 1.21
Astrocytic localization of kynurenine aminotransferase II in the rat brain visualized by immunocytochemistry. Glia (2007) 1.20
Astrocyte-derived kynurenic acid modulates basal and evoked cortical acetylcholine release. Eur J Neurosci (2009) 1.20
Modulatory role of presynaptic nicotinic receptors in synaptic and non-synaptic chemical communication in the central nervous system. Brain Res Brain Res Rev (1999) 1.20
Impaired kynurenine pathway metabolism in the prefrontal cortex of individuals with schizophrenia. Schizophr Bull (2010) 1.19
Expression of the kynurenine pathway enzymes in human microglia and macrophages. Adv Exp Med Biol (2003) 1.13
Kynurenic acid leads, dopamine follows: a new case of volume transmission in the brain? J Neural Transm (Vienna) (2006) 1.12
On the relationship between the two branches of the kynurenine pathway in the rat brain in vivo. J Neurochem (2009) 1.11
Presynaptic alpha7 and non-alpha7 nicotinic acetylcholine receptors modulate [3H]d-aspartate release from rat frontal cortex in vitro. Neuropharmacology (2005) 1.08
Transient N-methyl-D-aspartate receptor blockade in early development causes lasting cognitive deficits relevant to schizophrenia. Biol Psychiatry (2005) 1.08
Specific inhibition of kynurenate synthesis enhances extracellular dopamine levels in the rodent striatum. Neuroscience (2008) 1.07
Regulation of nicotinic acetylcholine receptor channel function by acetylcholinesterase inhibitors in rat hippocampal CA1 interneurons. Mol Pharmacol (2004) 1.07
Inflammatory cytokines and neurological and neurocognitive alterations in the course of schizophrenia. Biol Psychiatry (2013) 1.06
Acute elevations of brain kynurenic acid impair cognitive flexibility: normalization by the alpha7 positive modulator galantamine. Psychopharmacology (Berl) (2011) 1.06
Kynurenic acid: a metabolite with multiple actions and multiple targets in brain and periphery. J Neural Transm (Vienna) (2012) 1.05
Pre- and postnatal exposure to kynurenine causes cognitive deficits in adulthood. Eur J Neurosci (2012) 1.04
The kynurenine pathway as a therapeutic target in cognitive and neurodegenerative disorders. Br J Pharmacol (2013) 1.04
Glutamate and nicotinic receptor interactions in working memory: importance for the cognitive impairment of schizophrenia. Neuroscience (2011) 1.03
Different nicotinic acetylcholine receptor subtypes mediating striatal and prefrontal cortical [3H]dopamine release. Neuropharmacology (2005) 1.03
Distribution of mRNAs encoding the arylhydrocarbon receptor, arylhydrocarbon receptor nuclear translocator, and arylhydrocarbon receptor nuclear translocator-2 in the rat brain and brainstem. J Comp Neurol (2000) 1.02
Cerebral energy metabolism, glucose transport and blood flow: changes with maturation and adaptation to hypoglycaemia. Diabetes Metab (1997) 1.02
Biochemical and phenotypic abnormalities in kynurenine aminotransferase II-deficient mice. Mol Cell Biol (2004) 1.01
The aryl hydrocarbon receptor meets immunology: friend or foe? A little of both. Front Immunol (2014) 1.01
Receptors for alpha-bungarotoxin in the developing visual system of the chick. Brain Res (1976) 1.01
Age dependency of inhibition of alpha7 nicotinic receptors and tonically active N-methyl-D-aspartate receptors by endogenously produced kynurenic acid in the brain. J Pharmacol Exp Ther (2011) 1.00
Prenatal exposure to an NMDA receptor antagonist, MK-801 reduces density of parvalbumin-immunoreactive GABAergic neurons in the medial prefrontal cortex and enhances phencyclidine-induced hyperlocomotion but not behavioral sensitization to methamphetamine in postpubertal rats. Psychopharmacology (Berl) (2007) 1.00
The excitatory amino acid antagonist kynurenic acid administered after hypoxic-ischemia in neonatal rats offers neuroprotection. Neurosci Lett (1988) 1.00
Differences in distribution of ages of onset in males and females with schizophrenia. Schizophr Res (1998) 0.99
Neonatal infection with neurotropic influenza A virus induces the kynurenine pathway in early life and disrupts sensorimotor gating in adult Tap1-/- mice. Int J Neuropsychopharmacol (2009) 0.99
Fluctuations in endogenous kynurenic acid control hippocampal glutamate and memory. Neuropsychopharmacology (2011) 0.98
Expression of aryl hydrocarbon receptor in human placentas and fetal tissues. J Histochem Cytochem (2010) 0.98
Neuroprotective and memory-related actions of novel alpha-7 nicotinic agents with different mixed agonist/antagonist properties. J Pharmacol Exp Ther (1998) 0.98
Obstetric risk factors for early-onset schizophrenia in a Finnish birth cohort. Am J Psychiatry (2000) 0.97
Early brain development disruption from NMDA receptor hypofunction: relevance to schizophrenia. Brain Res Rev (2006) 0.96
A unifying hypothesis of schizophrenia: abnormal immune system development may help explain roles of prenatal hazards, post-pubertal onset, stress, genes, climate, infections, and brain dysfunction. Med Hypotheses (2010) 0.96
Competitive antagonism between the nicotinic allosteric potentiating ligand galantamine and kynurenic acid at alpha7* nicotinic receptors. J Pharmacol Exp Ther (2007) 0.95
Stimulation of the N-methyl-D-aspartate receptor has a trophic effect on differentiating cerebellar granule cells. Neurosci Lett (1988) 0.94
Allosteric modulation of alpha 7 nicotinic receptors selectively depolarizes hippocampal interneurons, enhancing spontaneous GABAergic transmission. Eur J Neurosci (2008) 0.94
Discovery of Brain-Penetrant, Irreversible Kynurenine Aminotransferase II Inhibitors for Schizophrenia. ACS Med Chem Lett (2012) 0.94
On the excitotoxic properties of quinolinic acid, 2,3-piperidine dicarboxylic acids and structurally related compounds. Neuropharmacology (1983) 0.94
Cortical kynurenic acid bi-directionally modulates prefrontal glutamate levels as assessed by microdialysis and rapid electrochemistry. Neuroscience (2010) 0.93
Targeted deletion of kynurenine 3-monooxygenase in mice: a new tool for studying kynurenine pathway metabolism in periphery and brain. J Biol Chem (2013) 0.93
Localisation of indoleamine 2,3-dioxygenase and kynurenine hydroxylase in the human placenta and decidua: implications for role of the kynurenine pathway in pregnancy. Placenta (2005) 0.93
Plasticity in the tectum of Xenopus laevis: binocular maps. Prog Neurobiol (1999) 0.93
Chronic neuroleptic treatment reduces endogenous kynurenic acid levels in rat brain. J Neural Transm (Vienna) (2006) 0.92
Reduction of brain kynurenic acid improves cognitive function. J Neurosci (2014) 0.91
Exposure to kynurenic acid during adolescence produces memory deficits in adulthood. Schizophr Bull (2010) 0.91
Second-by-second measurement of acetylcholine release in prefrontal cortex. Eur J Neurosci (2006) 0.91
Brain-specific modulation of kynurenic acid synthesis in the rat. J Neurochem (1997) 0.91
Tryptophan 2,3-dioxygenase and indoleamine 2,3-dioxygenase 1 make separate, tissue-specific contributions to basal and inflammation-induced kynurenine pathway metabolism in mice. Biochim Biophys Acta (2016) 0.86
Restraint Stress during Pregnancy Rapidly Raises Kynurenic Acid Levels in Mouse Placenta and Fetal Brain. Dev Neurosci (2017) 0.75